<DOC>
	<DOCNO>NCT01889238</DOCNO>
	<brief_summary>The purpose study determine enzalutamide safe effective treatment patient advance breast cancer express androgen receptor express estrogen progesterone receptor Her2 amplify .</brief_summary>
	<brief_title>Safety Efficacy Study Enzalutamide Patients With Advanced , Androgen Receptor-Positive , Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Women least 18 year age ; Advanced AR+ TNBC ; Availability representative tumor specimen : Either measurable disease bone nonmeasurable disease ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Any severe concurrent disease , infection , comorbid condition ; Any condition reason interfere patient 's ability participate trial , may cause undue risk , complicate interpretation safety data ; Current previously treat brain metastasis active leptomeningeal disease ; Current hormone replacement therapy ; Local palliative radiation therapy within 7 day day 1 ; History another invasive cancer within 5 year day 1 ; Absolute neutrophil count &lt; 1500/µL , platelet count &lt; 75,000/µL , hemoglobin &lt; 9 g/dL ( 5.6 mmol/L ) screen visit ; Creatinine &gt; 1.5 time upper limit normal ( ULN ) screen visit ; History seizure condition may predispose seizure ; Clinically significant cardiovascular disease ; Active gastrointestinal disorder affect absorption ; Major surgery within 4 week day 1 ; Treatment commercially available anticancer agent within 14 day day 1 ; Treatment investigational agent within 2 week day 1 ; Treatment follow medication within 2 week day 1 : Estrogens , include hormone replacement therapy ; Androgens ( testosterone , dihydroepiandrosterone , etc ) ; Systemic radionuclides ( eg , samarium strontium ) ; Vaccine therapy ; Hypoglycemic episode require medical intervention insulin treatment within 12 month day 1 ; Hypersensitivity reaction active pharmaceutical ingredient capsule component , include Labrasol , butylate hydroxyanisole , butylate hydroxytoluene .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>triple negative</keyword>
	<keyword>androgen receptor positive</keyword>
</DOC>